BDRX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

23 days ago - By: Benzinga - Mentions: PDEX NDRA SRRK IMAB ...

12 Health Care Stocks Moving In Monday's Intraday Session

26 days ago - By: Benzinga - Mentions: ONMD ANVS XBIO PTGX ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 months ago - By: ACCESS Newswire

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

3 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change Effective

4 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change

5 months ago - By: Biodexa Pharmaceuticals PLC

Result of General Meeting

a month ago - By: Biodexa Pharmaceuticals PLC

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

2 months ago - By: Biodexa Pharmaceuticals PLC

Interim results for the six months ended June 30, 2025

2 months ago - By: Zacks Investment Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

5 months ago - By: Biodexa Pharmaceuticals PLC

Shareholder Update

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

3 months ago - By: ACCESS Newswire

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

4 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

4 months ago - By: Biodexa Pharmaceuticals PLC

Results of Annual General Meeting

4 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

5 months ago - By: ACCESS Newswire

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

5 months ago - By: Yahoo Finance - Mentions: RY RY.CA SEDG PATH ...

UiPath price target raised to $15 from $12 at TD Cowen

5 months ago - By: Yahoo Finance - Mentions: HRI HEES PD PATH ...

Herc Holdings, H&E Equipment announce expiration of tender offer

5 months ago - By: Yahoo Finance - Mentions: BLRX SEDG PD WETO ...

BioLineRx upgraded to Buy from Hold at JonesResearch

5 months ago - By: Yahoo Finance - Mentions: RY RY.CA SPWR PD ...

PagerDuty price target lowered to $17 from $18 at TD Cowen

5 months ago - By: Yahoo Finance - Mentions: RY RY.CA ULTA ZS ...

Zscaler price target raised to $290 from $245 at Evercore ISI

5 months ago - By: Yahoo Finance - Mentions: DHI CMG

Biodexa Pharmaceuticals sees cash runway into 1Q26

5 months ago - By: Yahoo Finance - Mentions: LMT JPM SEDG LHX ...

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock News

BDRX Latest News, Press Relases and Analysis

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

ADR Ratio Change Effective

ADR Ratio Change

Result of General Meeting

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Shareholder Update

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

UiPath price target raised to $15 from $12 at TD Cowen

Herc Holdings, H&E Equipment announce expiration of tender offer

BioLineRx upgraded to Buy from Hold at JonesResearch

PagerDuty price target lowered to $17 from $18 at TD Cowen

Zscaler price target raised to $290 from $245 at Evercore ISI

Biodexa Pharmaceuticals sees cash runway into 1Q26

L3Harris Technologies price target raised to $270 from $240 at TD Cowen